Hellenic Business Awards 2026 Most Innovative Bioinformatics Platform 2026: OboroBio The metagenomics landscape is shifting; the first generation of molecular biology tools significantly contributed to the identification of microbial presence. Now, the next generation of tools and systems are being built to help organisations understand what those observations mean in context, how they are changing over time, what evidence supports their significance, and what deserves attention. This transition from detection to understanding reflects the broader transformation that Athens-based DNA Sequencing SRL is trying to support. We heard more from Co-Founder and Chief Technology Officer Christos Karapiperis. “Our objective is not simply to identify microorganisms, but to help organisations understand what those findings mean, how they relate to risk, and what action should follow. Established in 2019, DNA Sequence is a biotechnology and bioinformatics company focused on transforming complex microbial and biological data into actionable intelligence. The company combines laboratory capabilities with an AI-native software and data architecture, operating at the intersection of metagenomics, computational biology, artificial intelligence, knowledge engineering, and One Health. Central to DNA Sequence’s technology strategy is Oboro Bio, its developing microbial and One Health intelligence platform. Oboro Bio is being designed as an ontology-, evidence-, and workflow-driven environment that connects biological observations with contextual, environmental, epidemiological, operational, and scientific knowledge. Rather than treating sequencing results as isolated laboratory reports, the platform aims to represent them as part of a continuously evolving knowledge and evidence system. The principal application areas of Oboro Bio span drinking-water monitoring, environmental biosurveillance, infectious-disease and antimicrobial-resistance surveillance, environmental microbiology, and broader One Health applications. It targets clients across water utilities, healthcare settings, public health authorities, environmental organisations, laboratories, research institutes, biotechnology companies, sequencing organisations, food and agricultural stakeholders, and government or critical-infrastructure organisations. “Many of these clients already generate significant volumes of laboratory, sequencing, environmental, operational, or epidemiological data,” said Christos. “The problem is often not the absence of data, but fragmentation: information exists across laboratory reports, databases, spreadsheets, publications, monitoring systems, and expert knowledge, without a common semantic and evidentiary framework. Oboro Bio is intended to address this fragmentation.” A key element of this approach is the One Health ontology and evidence architecture. DNA Sequence is designing a common semantic core capable of representing microorganisms, samples, environments, hots, hazards, observations, analytical results, interventions, evidence, uncertainty, and the relationships between them. With individual clients able to operate isolated data and knowledge graphs, the platform preserves customer-specific confidentiality while creating a reusable intelligence layer across multiple sectors and use cases. This is supported by institutional memory. In many scientific and operational organisations, critical knowledge remains dispersed between individuals, reports, and disconnected systems. When personnel change, much of this knowledge is lost. With this challenge in mind, DNA Sequence has developed Oboro Bio to progressively capture not only data, but also evidence, analytical context, decisions, data-quality limitations, and the reasoning supporting previous actions. Over time, this can create a persistent microbial intelligence environment in which every new observation can be compared with accumulated evidence and knowledge. Underpinning this development is DNA Sequence’s core ethos that large language models should not replace validated bioinformatics methods or laboratory science. While it recognises that AI can help retrieve evidence, connect information, identify patterns, generate hypotheses, coordinate specialised analytical agents, explain findings, and support experts, DNA Sequence asserts that the underlying provenance, evidence, and uncertainty must remain visible. This philosophy is central to Oboro Bio. The remainder of 2026 represents an important transition period for DNA Sequence, as it moves from a company primarily recognised for advanced metagenomics and laboratory capacity towards a broader technology and intelligence model built around Oboro Bio. In the longer term, DNA Sequence sees Oboro Bio evolving towards a system that can support continuous microbial intelligence, enabling organisations to maintain an ongoing understanding of their microbial environment. Ultimately, 2026 and the years ahead represent a deliberate evolution for us, as we transitioning from a metagenomics service company into a broader AI-native microbial intelligence company,” Christos concluded. “The foundation remains rigorous laboratory science and deterministic bioinformatics, but around that we are building a new layer of structured knowledge, evidence, governed AI, and institutional memory. Our aim is to create a platform that helps organisations move from simply detecting microorganisms to understanding what those observations mean, how they relate to previous events, and what evidence should inform the next decision. “That is the direction in which we are investing our time and resources now. If we are successful, Oboro Bio will not simply be another analytical platform. It will become a persistent intelligence environment for understanding microbial systems across water, healthcare, environment, and the wider One Health landscape.” Contact Details Contact: Christos Karapiperis Company: DNA Sequence SRL Web Address: www.dna-sequence.eu
RkJQdWJsaXNoZXIy MTUyMDQwMA==